Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. MRNA
10. KNX

Go back to Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals (SNDX) Tops Q1 EPS by 11c, Revenues Beat

May 11, 2021 4:40 PM EDT

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q1 EPS of ($0.54), $0.11 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $379 thousand versus the consensus estimate of $220 thousand.

"We are excited to provide an update on the positive interim Phase 1 data from the ongoing AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia rearranged (MLLr) and nucleophosmin (NPM1c) mutant acute leukemias," said... More